News Biogen shares up after strong launch for rare disease drug US insurers are covering the treatment, despite high price.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Teva's CEO Vigodman steps down Firm searches for new leader, chairman takes over on interim basis.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
